 One or more interim analyses will be undertaken to guide decisions on 1 the potential use of the vaccine in Ph23 trials in affected countries and 2 potential modification of the trials through an amendment to evaluate a higher dose, if immunogenicity is poor, or a lower dose if the dosage levels selected are not safe and reasonably well tolerated. 